These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 36440187)
1. The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review. Urquhart C; Fleming B; Harper I; Aloj L; Armstrong R; Hook L; Long AM; Jackson C; Gallagher FA; McLean MA; Tarpey P; Kosmoliaptsis V; Nicholson J; Hendriks AEJ; Casey RT Front Endocrinol (Lausanne); 2022; 13():1066208. PubMed ID: 36440187 [TBL] [Abstract][Full Text] [Related]
2. Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma-Case Report and Review of the Literature. Tong A; Li M; Cui Y; Ma X; Wang H; Li Y Front Endocrinol (Lausanne); 2020; 11():61. PubMed ID: 32132978 [No Abstract] [Full Text] [Related]
4. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622 [TBL] [Abstract][Full Text] [Related]
5. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations. Zelinka T; Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Reynolds JC; Ling A; Eisenhofer G; Lazúrová I; Adams KT; Whatley MA; Widimsky J; Pacak K Endocr Relat Cancer; 2008 Mar; 15(1):311-23. PubMed ID: 18310297 [TBL] [Abstract][Full Text] [Related]
6. The utility of Jaiswal SK; Sarathi V; Malhotra G; Hira P; Shah R; Patil VA; Dalvi A; Prakash G; Lila AR; Shah NS; Bandgar T J Pediatr Endocrinol Metab; 2021 Jan; 34(1):109-119. PubMed ID: 33180042 [TBL] [Abstract][Full Text] [Related]
7. Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma: a retrospective multicenter cohort study. Fischer A; Kloos S; Remde H; Dischinger U; Pamporaki C; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Bechmann N; Hantel C; Mohr H; Pellegata NS; Bornstein SR; Kroiss M; Auernhammer CJ; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S Eur J Endocrinol; 2023 Nov; 189(5):546-565. PubMed ID: 37949483 [TBL] [Abstract][Full Text] [Related]
8. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Ling A; Eisenhofer G; Adams KT; Solis D; Lenders JW; Pacak K J Clin Oncol; 2007 Jun; 25(16):2262-9. PubMed ID: 17538171 [TBL] [Abstract][Full Text] [Related]
9. Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma. Janssen I; Blanchet EM; Adams K; Chen CC; Millo CM; Herscovitch P; Taieb D; Kebebew E; Lehnert H; Fojo AT; Pacak K Clin Cancer Res; 2015 Sep; 21(17):3888-95. PubMed ID: 25873086 [TBL] [Abstract][Full Text] [Related]
10. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. van Nederveen FH; Gaal J; Favier J; Korpershoek E; Oldenburg RA; de Bruyn EM; Sleddens HF; Derkx P; Rivière J; Dannenberg H; Petri BJ; Komminoth P; Pacak K; Hop WC; Pollard PJ; Mannelli M; Bayley JP; Perren A; Niemann S; Verhofstad AA; de Bruïne AP; Maher ER; Tissier F; Méatchi T; Badoual C; Bertherat J; Amar L; Alataki D; Van Marck E; Ferrau F; François J; de Herder WW; Peeters MP; van Linge A; Lenders JW; Gimenez-Roqueplo AP; de Krijger RR; Dinjens WN Lancet Oncol; 2009 Aug; 10(8):764-71. PubMed ID: 19576851 [TBL] [Abstract][Full Text] [Related]
11. SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma. Perez K; Jacene H; Hornick JL; Ma C; Vaz N; Brais LK; Alexander H; Baddoo W; Astone K; Esplin ED; Garcia J; Halperin DM; Kulke MH; Chan JA Endocr Relat Cancer; 2022 Sep; 29(9):533-544. PubMed ID: 35731023 [TBL] [Abstract][Full Text] [Related]
12. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters. van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126 [TBL] [Abstract][Full Text] [Related]
13. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Havekes B; Eisenhofer G; Martiniova L; Adams KT; Pacak K J Clin Endocrinol Metab; 2009 Dec; 94(12):4757-67. PubMed ID: 19864450 [TBL] [Abstract][Full Text] [Related]
15. Clinical Practice Guidance: Surveillance for phaeochromocytoma and paraganglioma in paediatric succinate dehydrogenase gene mutation carriers. Wong MY; Andrews KA; Challis BG; Park SM; Acerini CL; Maher ER; Casey RT Clin Endocrinol (Oxf); 2019 Apr; 90(4):499-505. PubMed ID: 30589099 [TBL] [Abstract][Full Text] [Related]
16. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Taïeb D; Jha A; Treglia G; Pacak K Endocr Relat Cancer; 2019 Nov; 26(11):R627-R652. PubMed ID: 31561209 [TBL] [Abstract][Full Text] [Related]
17. Variant type is associated with disease characteristics in SDHB, SDHC and SDHD-linked phaeochromocytoma-paraganglioma. Bayley JP; Bausch B; Rijken JA; van Hulsteijn LT; Jansen JC; Ascher D; Pires DEV; Hes FJ; Hensen EF; Corssmit EPM; Devilee P; Neumann HPH J Med Genet; 2020 Feb; 57(2):96-103. PubMed ID: 31492822 [TBL] [Abstract][Full Text] [Related]
18. 18 F-MFBG PET/CT Is an Effective Alternative of 68 Ga-DOTATATE PET/CT in the Evaluation of Metastatic Pheochromocytoma and Paraganglioma. Wang P; Li T; Cui Y; Zhuang H; Li F; Tong A; Jing H Clin Nucl Med; 2023 Jan; 48(1):43-48. PubMed ID: 36252940 [TBL] [Abstract][Full Text] [Related]
19. Comparison of 18 F-MFBG and 68 Ga-DOTATATE PET/CT in the Imaging of Metastatic Paraganglioma and Pheochromocytoma. Deng M; Shu Q; Hu M; Chen Y; Cai L Clin Nucl Med; 2022 Dec; 47(12):e735-e737. PubMed ID: 35777982 [TBL] [Abstract][Full Text] [Related]
20. Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials. Severi S; Bongiovanni A; Ferrara M; Nicolini S; Di Mauro F; Sansovini M; Lolli I; Tardelli E; Cittanti C; Di Iorio V; Mezzenga E; Scarpi E; Ibrahim T; Paganelli G; Zovato S ESMO Open; 2021 Aug; 6(4):100171. PubMed ID: 34139487 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]